Sabra Healthcare REIT (NASDAQ:SBRA) Issues FY 2026 Earnings Guidance

Sabra Healthcare REIT (NASDAQ:SBRA) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 1.540-1.550 for the period, compared to the consensus earnings per share estimate of 1.520.

Sabra Healthcare REIT Price Performance

Sabra Healthcare REIT stock opened at $19.72 on Tuesday. The firm has a market capitalization of $5.04 billion, a PE ratio of 75.85, a P/E/G ratio of 1.73 and a beta of 0.63. Sabra Healthcare REIT has a 52 week low of $17.53 and a 52 week high of $22.77. The firm’s 50-day simple moving average is $19.86 and its 200 day simple moving average is $19.96. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.95.

Sabra Healthcare REIT (NASDAQ:SBRA) last issued its quarterly earnings data on Monday, November 2nd. The real estate investment trust reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.05). The company had revenue of $249.57 million for the quarter, compared to analyst estimates of $236.64 million. Sabra Healthcare REIT had a return on equity of 2.34% and a net margin of 7.61%. The company’s revenue for the quarter was up 31.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.38 earnings per share. On average, equities research analysts predict that Sabra Healthcare REIT will post 1.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SBRA has been the subject of several research analyst reports. Wells Fargo & Company dropped their price target on Sabra Healthcare REIT from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Monday, October 19th. Raymond James Financial raised Sabra Healthcare REIT from an “underperform” rating to a “market perform” rating in a research note on Thursday, August 6th. Citizens Jmp boosted their target price on Sabra Healthcare REIT from $23.00 to $25.00 and gave the stock a “market outperform” rating in a report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sabra Healthcare REIT in a report on Wednesday, July 22nd. Finally, Truist Financial increased their target price on shares of Sabra Healthcare REIT from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $21.50.

Insider Transactions at Sabra Healthcare REIT

In other Sabra Healthcare REIT news, CEO Richard Matros sold 200,000 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $20.83, for a total transaction of $4,166,000.00. Following the transaction, the chief executive officer directly owned 1,657,686 shares in the company, valued at $34,529,599.38. This represents a 10.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.09% of the stock is owned by corporate insiders.

Key Headlines Impacting Sabra Healthcare REIT

Here are the key news stories impacting Sabra Healthcare REIT this week:

• Positive Sentiment: Sabra reported third-quarter earnings of $0.41 per diluted share, exceeding the consensus estimate of $0.16 and rising from $0.38 in the year-ago quarter. Revenue increased 31.4% year over year to $249.6 million, ahead of the $236.6 million analyst estimate. Earnings Flash
• Positive Sentiment: Key REIT performance measures were solid: third-quarter FFO was $0.40 per share, normalized FFO was $0.39, AFFO was $0.45 and normalized AFFO was $0.41. FFO surpassed the $0.40 consensus estimate and increased from $0.38 a year earlier. Sabra Tops Q3 FFO and Revenue Estimates
• Positive Sentiment: Management raised 2026 EPS guidance to $1.54-$1.55, above the $1.52 consensus forecast. The higher outlook may support investor confidence in operating performance and cash-generation prospects. Sabra Reports Third Quarter 2026 Results and Updates Guidance
• Positive Sentiment: Sabra also declared its quarterly dividend, reinforcing the stock’s income appeal for REIT investors. Sabra Reports Results and Declares Dividend
• Neutral Sentiment: Despite the earnings beat and improved guidance, the shares were little changed, suggesting investors may have largely anticipated the strong results or remain focused on REIT-specific factors such as interest rates, leverage and healthcare-property risks.

About Sabra Healthcare REIT

Sabra Healthcare REIT, Inc is a self-managed real estate investment trust that owns and invests in healthcare-related real estate. The company focuses primarily on properties used for skilled nursing and transitional care, senior housing, behavioral health, specialty hospitals and other healthcare services.

Sabra leases properties to healthcare operators and also provides capital through loans, joint ventures and other real estate investments. Its portfolio is designed to support a range of care settings, including facilities serving seniors, patients requiring rehabilitation and individuals receiving behavioral healthcare.

Founded in 2010 and headquartered in Irvine, California, Sabra has expanded through acquisitions, development investments and strategic transactions, including its 2017 combination with Care Capital Properties.